Perspectives on host adaptation in response to Mycobacterium tuberculosis: Modulation of inflammation

Seminars in Immunology

Volumn 26, Issue 6, 2014, Pages 533-542

  Dorhoi, Anca ^a   Kaufmann, Stefan H E ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

Cavitation; Immunopathology; Inflammation; Lung; Mycobacterium tuberculosis; Regulatory cytokines

Indexed keywords

INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ADAPTATION; CELLS; DISEASE COURSE; HELPER CELL; HOST RESISTANCE; INFLAMMATION; LUNG CAVITATION; LUNG GRANULOMA; LYMPHOCYTE; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; REGULATORY T LYMPHOCYTE; REVIEW; TUBERCULOSIS; GENE EXPRESSION REGULATION; GENETICS; GRANULOMA; HUMAN; IMMUNE EVASION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LUNG; LUNG ALVEOLUS CELL; LUNG TUBERCULOSIS; MICROBIOLOGY; NEUTROPHIL; PATHOLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

CYTOKINES; GENE EXPRESSION REGULATION; GRANULOMA; HUMANS; IMMUNE EVASION; IMMUNE TOLERANCE; INFLAMMATION; LUNG; MACROPHAGES; MYCOBACTERIUM TUBERCULOSIS; NEUTROPHILS; PNEUMOCYTES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUBERCULOSIS, PULMONARY;

EID: 84920059777     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2014.10.002     Document Type: Review

References (217)

1. Nathan C. Points of control in inflammation. Nature 2002, 420(December (6917)):846-852.
2. Kolaczkowska E., Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 2013, 13(March (3)):159-175.
3. Levy B.D., Serhan C.N. Resolution of acute inflammation in the lung. Annu Rev Physiol 2014, 76:467-492.
4. Nathan C., Ding A. Nonresolving inflammation. Cell 2010, 140(March (6)):871-882.
5. Shi C., Pamer E.G. Monocyte recruitment during infection inflammation. Nat Rev Immunol 2011, 11(November (11)):762-774.
6. Basaraba R.J. Experimental tuberculosis: the role of comparative pathology in the discovery of improved tuberculosis treatment strategies. Tuberculosis (Edinb) 2008, 88(August (Suppl. 1)):S35-S47.
7. Ernst J.D. The immunological life cycle of tuberculosis. Nat Rev Immunol 2012, 12(August (8)):581-591.
8. Kaushal D., Mehra S., Didier P.J., Lackner A.A. The non-human primate model of tuberculosis. J Med Primatol 2012, 41(June (3)):191-201.
9. O'Garra A., Redford P.S., McNab F.W., Bloom C.I., Wilkinson R.J., Berry M.P. The immune response in tuberculosis. Annu Rev Immunol 2013, 31:475-527.
10. Ramakrishnan L. The zebrafish guide to tuberculosis immunity and treatment. Cold Spring Harb Symp Quant Biol 2013, 78:179-192.
11. Marino S., Linderman J.J., Kirschner D.E. A multifaceted approach to modeling the immune response in tuberculosis. Wiley Interdiscip Rev Syst Biol Med 2011, 3(July (4)):479-489.
12. Kaufmann S.H., Cole S.T., Mizrahi V., Rubin E., Nathan C. Mycobacterium tuberculosis and the host response. J Exp Med 2005, 201(June (11)):1693-1697.
13. Gengenbacher M., Kaufmann S.H. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev 2012, 36(May (3)):514-532.
14. Holt P.G., Strickland D.H., Wikstrom M.E., Jahnsen F.L. Regulation of immunological homeostasis in the respiratory tract. Nat Rev Immunol 2008, 8(February (2)):142-152.
15. Hussell T., Bell T.J. Alveolar macrophages: plasticity in a tissue-specific context. Nat Rev Immunol 2014, 14(February (2)):81-93.
16. Blomgran R., Ernst J.D. Lung neutrophils facilitate activation of naive antigen-specific CD4+ T cells during Mycobacterium tuberculosis infection. J Immunol 2011, 186(June (12)):7110-7119.
17. Kang D.D., Lin Y., Moreno J.R., Randall T.D., Khader S.A. Profiling early lung immune responses in the mouse model of tuberculosis. PLoS ONE 2011, 6(1):e16161.
18. Abakay O., Abakay A., Sen H.S., Tanrikulu A.C. The relationship between inflammatory marker levels and pulmonary tuberculosis severity. Inflammation 2014, (July). Epub ahead of print. 10.1007/s10753-014-9978-y.
19. Lowe D.M., Bandara A.K., Packe G.E., Barker R.D., Wilkinson R.J., Griffiths C.J., et al. Neutrophilia independently predicts death in tuberculosis. Eur Respir J 2013, 42(December (6)):1752-1757.
20. Eruslanov E.B., Lyadova I.V., Kondratieva T.K., Majorov K.B., Scheglov I.V., Orlova M.O., et al. Neutrophil responses to Mycobacterium tuberculosis infection in genetically susceptible and resistant mice. Infect Immun 2005, 73(March (3)):1744-1753.
21. Keller C., Hoffmann R., Lang R., Brandau S., Hermann C., Ehlers S. Genetically determined susceptibility to tuberculosis in mice causally involves accelerated and enhanced recruitment of granulocytes. Infect Immun 2006, 74(July (7)):4295-4309.
22. Gopal R., Monin L., Torres D., Slight S., Mehra S., McKenna K.C., et al. S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology during tuberculosis. Am J Respir Crit Care Med 2013, 188(November (9)):1137-1146.
23. Dorhoi A., Iannaccone M., Maertzdorf J., Nouailles G., Weiner J., Kaufmann S.H. Reverse translation in tuberculosis: neutrophils provide clues for understanding development of active disease. Front Immunol 2014, 5:36.
24. Marzo E., Vilaplana C., Tapia G., Diaz J., Garcia V., Cardona P.J. Damaging role of neutrophilic infiltration in a mouse model of progressive tuberculosis. Tuberculosis (Edinb) 2014, 94(January (1)):55-64.
25. Ong C.W., Elkington P.T., Friedland J.S. Tuberculosis, pulmonary cavitation, and matrix metalloproteinases. Am J Respir Crit Care Med 2014, 190(July (1)):9-18.
26. Orme I.M. A new unifying theory of the pathogenesis of tuberculosis. Tuberculosis (Edinb) 2014, 94(January (1)):8-14.
27. Eum S.Y., Kong J.H., Hong M.S., Lee Y.J., Kim J.H., Hwang S.H., et al. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 2010, 137(January (1)):122-128.
28. McCarter Y.S., Robinson A. Quality evaluation of sputum specimens for mycobacterial culture. Am J Clin Pathol 1996, 105(June (6)):769-773.
29. Rock J.R., Hogan B.L. Epithelial progenitor cells in lung development, maintenance, repair, and disease. Annu Rev Cell Dev Biol 2011, 27:493-512.
30. Desvignes L., Ernst J.D. Interferon-gamma-responsive nonhematopoietic cells regulate the immune response to Mycobacterium tuberculosis. Immunity 2009, 31(December (6)):974-985.
31. Weiner J., Parida S.K., Maertzdorf J., Black G.F., Repsilber D., Telaar A., et al. Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS ONE 2012, 7(7):e40221.
32. Slight S.R., Rangel-Moreno J., Gopal R., Lin Y., Fallert Junecko B.A., Mehra S., et al. CXCR5(+) T helper cells mediate protective immunity against tuberculosis. J Clin Invest 2013, 123(February (2)):712-726.
33. Mattila J.T., Ojo O.O., Kepka-Lenhart D., Marino S., Kim J.H., Eum S.Y., et al. Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. J Immunol 2013, 191(July (2)):773-784.
34. Repasy T., Lee J., Marino S., Martinez N., Kirschner D.E., Hendricks G., et al. Intracellular bacillary burden reflects a burst size for Mycobacterium tuberculosis in vivo. PLoS Pathog 2013, 9(February (2)):e1003190.
35. Wolf A.J., Linas B., Trevejo-Nunez G.J., Kincaid E., Tamura T., Takatsu K., et al. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol 2007, 179(August (4)):2509-2519.
36. Divangahi M., Chen M., Gan H., Desjardins D., Hickman T.T., Lee D.M., et al. Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair. Nat Immunol 2009, 10(August (8)):899-906.
37. Dorhoi A., Yeremeev V., Nouailles G., Weiner J., Jorg S., Heinemann E., et al. Type I IFN signaling triggers immunopathology in tuberculosis-susceptible mice by modulating lung phagocyte dynamics. Eur J Immunol 2014, (April). 10.1002/eji.201344219.
38. van C.R., Ottenhoff T.H., van der Meer J.W. Innate immunity to Mycobacterium tuberculosis. Clin Microbiol Rev 2002, 15(April (2)):294-309.
39. Ernst J.D. Macrophage receptors for Mycobacterium tuberculosis. Infect Immun 1998, 66(April (4)):1277-1281.
40. Schlesinger L.S., Bellinger-Kawahara C.G., Payne N.R., Horwitz M.A. Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3. J Immunol 1990, 144(April (7)):2771-2780.
41. Schlesinger L.S. Macrophage phagocytosis of virulent but not attenuated strains of Mycobacterium tuberculosis is mediated by mannose receptors in addition to complement receptors. J Immunol 1993, 150(April (7)):2920-2930.
42. Geijtenbeek T.B., Van Vliet S.J., Koppel E.A., Sanchez-Hernandez M., Vandenbroucke-Grauls C.M., Appelmelk B., et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med 2003, 197(January (1)):7-17.
43. Tailleux L., Pham-Thi N., Bergeron-Lafaurie A., Herrmann J.L., Charles P., Schwartz O., et al. DC-SIGN induction in alveolar macrophages defines privileged target host cells for mycobacteria in patients with tuberculosis. PLoS Med 2005, 2(December (12)):e381.
44. Tanne A., Ma B., Boudou F., Tailleux L., Botella H., Badell E., et al. A murine DC-SIGN homologue contributes to early host defense against Mycobacterium tuberculosis. J Exp Med 2009, 206(September (10)):2205-2220.
45. Aderem A., Underhill D.M. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol 1999, 17:593-623.
46. Le C., Carreno V., Moisand S., Bordier A., Maridonneau-Parini C.I. Complement receptor 3 (CD11b/CD18) mediates type I and type II phagocytosis during nonopsonic and opsonic phagocytosis, respectively. J Immunol 2002, 169(August (4)):2003-2009.
47. Velasco-Velazquez M.A., Barrera D., Gonzalez-Arenas A., Rosales C., Agramonte-Hevia J. Macrophage - Mycobacterium tuberculosis interactions: role of complement receptor 3. Microb Pathog 2003, 35(September (3)):125-131.
48. Ferguson J.S., Weis J.J., Martin J.L., Schlesinger L.S. Complement protein C3 binding to Mycobacterium tuberculosis is initiated by the classical pathway in human bronchoalveolar lavage fluid. Infect Immun 2004, 72(May (5)):2564-2573.
49. Cywes C., Hoppe H.C., Daffe M., Ehlers M.R. Nonopsonic binding of Mycobacterium tuberculosis to complement receptor type 3 is mediated by capsular polysaccharides and is strain dependent. Infect Immun 1997, 65(October (10)):4258-4266.
50. Cywes C., Godenir N.L., Hoppe H.C., Scholle R.R., Steyn L.M., Kirsch R.E., et al. Nonopsonic binding of Mycobacterium tuberculosis to human complement receptor type 3 expressed in Chinese hamster ovary cells. Infect Immun 1996, 64(December (12)):5373-5383.
51. Schorey J.S., Carroll M.C., Brown E.J. A macrophage invasion mechanism of pathogenic mycobacteria. Science 1997, 277(August (5329)):1091-1093.
52. Hu C., Mayadas-Norton T., Tanaka K., Chan J., Salgame P. Mycobacterium tuberculosis infection in complement receptor 3-deficient mice. J Immunol 2000, 165(September (5)):2596-2602.
53. Melo M.D., Catchpole I.R., Haggar G., Stokes R.W. Utilization of CD11b knockout mice to characterize the role of complement receptor 3 (CR3, CD11b/CD18) in the growth of Mycobacterium tuberculosis in macrophages. Cell Immunol 2000, 205(October (1)):13-23.
54. Rooyakkers A.W., Stokes R.W. Absence of complement receptor 3 results in reduced binding and ingestion of Mycobacterium tuberculosis but has no significant effect on the induction of reactive oxygen and nitrogen intermediates or on the survival of the bacteria in resident and interferon-gamma activated macrophages. Microb Pathog 2005, 39(September (3)):57-67.
55. Zimmerli S., Edwards S., Ernst J.D. Selective receptor blockade during phagocytosis does not alter the survival and growth of Mycobacterium tuberculosis in human macrophages. Am J Respir Cell Mol Biol 1996, 15(December (6)):760-770.
56. Sturgill-Koszycki S., Haddix P.L., Russell D.G. The interaction between Mycobacterium and the macrophage analyzed by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 1997, 18(December (14)):2558-2565.
57. Torrelles J.B., Azad A.K., Schlesinger L.S. Fine discrimination in the recognition of individual species of phosphatidyl-myo-inositol mannosides from Mycobacterium tuberculosis by C-type lectin pattern recognition receptors. J Immunol 2006, 177(August (3)):1805-1816.
58. Allavena P., Chieppa M., Monti P., Piemonti L. From pattern recognition receptor to regulator of homeostasis: the double-faced macrophage mannose receptor. Crit Rev Immunol 2004, 24(3):179-192.
59. Kang P.B., Azad A.K., Torrelles J.B., Kaufman T.M., Beharka A., Tibesar E., et al. The human macrophage mannose receptor directs Mycobacterium tuberculosis lipoarabinomannan-mediated phagosome biogenesis. J Exp Med 2005, 202(October (7)):987-999.
60. Astarie-Dequeker C., N'Diaye E.N., Le C., Rittig V., Prandi M.G., Maridonneau-Parini J.I. The mannose receptor mediates uptake of pathogenic and nonpathogenic mycobacteria and bypasses bactericidal responses in human macrophages. Infect Immun 1999, 67(February (2)):469-477.
61. Chieppa M., Bianchi G., Doni A., Del P.A., Sironi M., Laskarin G., et al. Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program. J Immunol 2003, 171(November (9)):4552-4560.
62. Nigou J., Zelle-Rieser C., Gilleron M., Thurnher M., Puzo G. Mannosylated lipoarabinomannans inhibit IL-12 production by human dendritic cells: evidence for a negative signal delivered through the mannose receptor. J Immunol 2001, 166(June (12)):7477-7485.
63. Rajaram M.V., Brooks M.N., Morris J.D., Torrelles J.B., Azad A.K., Schlesinger L.S. Mycobacterium tuberculosis activates human macrophage peroxisome proliferator-activated receptor gamma linking mannose receptor recognition to regulation of immune responses. J Immunol 2010, 185(July (2)):929-942.
64. Shaw T.C., Thomas L.H., Friedland J.S. Regulation of IL-10 secretion after phagocytosis of Mycobacterium tuberculosis by human monocytic cells. Cytokine 2000, 12(May (5)):483-486.
65. Schafer G., Jacobs M., Wilkinson R.J., Brown G.D. Non-opsonic recognition of Mycobacterium tuberculosis by phagocytes. J Innate Immun 2009, 1(3):231-243.
66. Dorhoi A., Desel C., Yeremeev V., Pradl L., Brinkmann V., Mollenkopf H.J., et al. The adaptor molecule CARD9 is essential for tuberculosis control. J Exp Med 2010, 207(April (4)):777-792.
67. McNab F.W., Ewbank J., Rajsbaum R., Stavropoulos E., Martirosyan A., Redford P.S., et al. TPL-2-ERK1/2 signaling promotes host resistance against intracellular bacterial infection by negative regulation of type I IFN production. J Immunol 2013, 191(August (4)):1732-1743.
68. Zhang X., Majlessi L., Deriaud E., Leclerc C., Lo-Man R. Coactivation of Syk kinase and MyD88 adaptor protein pathways by bacteria promotes regulatory properties of neutrophils. Immunity 2009, 31(November (5)):761-771.
69. Bai W., Liu H., Ji Q., Zhou Y., Liang L., Zheng R., et al. TLR3 regulates mycobacterial RNA-induced IL-10 production through the PI3K/AKT signaling pathway. Cell Signal 2014, 26(May (5)):942-950.
70. Kleinnijenhuis J., Oosting M., Joosten L.A., Netea M.G., van C.R. Innate immune recognition of Mycobacterium tuberculosis. Clin Dev Immunol 2011, 2011:405310.
71. Reiling N., Ehlers S., Holscher C. MyDths and un-TOLLed truths: sensor, instructive and effector immunity to tuberculosis. Immunol Lett 2008, 116(February (1)):15-23.
72. Roth S., Ruland J. Caspase recruitment domain-containing protein 9 signaling in innate immunity and inflammation. Trends Immunol 2013, 34(June (6)):243-250.
73. Redford P.S., Boonstra A., Read S., Pitt J., Graham C., Stavropoulos E., et al. Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung. Eur J Immunol 2010, 40(August (8)):2200-2210.
74. Higgins D.M., Sanchez-Campillo J., Rosas-Taraco A.G., Lee E.J., Orme I.M., Gonzalez-Juarrero M. Lack of IL-10 alters inflammatory and immune responses during pulmonary Mycobacterium tuberculosis infection. Tuberculosis (Edinb) 2009, 89(March (2)):149-157.
75. Jung Y.J., Ryan L., LaCourse R., North R.J. Increased interleukin-10 expression is not responsible for failure of T helper 1 immunity to resolve airborne Mycobacterium tuberculosis infection in mice. Immunology 2003, 109(June (2)):295-299.
76. Murray P.J., Young R.A. Increased antimycobacterial immunity in interleukin-10-deficient mice. Infect Immun 1999, 67(June (6)):3087-3095.
77. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991, 147(December (11)):3815-3822.
78. Murray P.J., Wang L., Onufryk C., Tepper R.I., Young R.A. T cell-derived IL-10 antagonizes macrophage function in mycobacterial infection. J Immunol 1997, 158(January (1)):315-321.
79. Schreiber T., Ehlers S., Heitmann L., Rausch A., Mages J., Murray P.J., et al. Autocrine IL-10 induces hallmarks of alternative activation in macrophages and suppresses antituberculosis effector mechanisms without compromising T cell immunity. J Immunol 2009, 183(July (2)):1301-1312.
80. Qualls J.E., Neale G., Smith A.M., Koo M.S., DeFreitas A.A., Zhang H., et al. Arginine usage in mycobacteria-infected macrophages depends on autocrine-paracrine cytokine signaling. Sci Signal 2010, 3(135):ra62.
81. O'Leary S., O'Sullivan M.P., Keane J. IL-10 blocks phagosome maturation in Mycobacterium tuberculosis-infected human macrophages. Am J Respir Cell Mol Biol 2011, 45(July (1)):172-180.
82. Chandra V., Mahajan S., Saini A., Dkhar H.K., Nanduri R., Raj E.B., et al. Human IL10 gene repression by Rev-erbalpha ameliorates Mycobacterium tuberculosis clearance. J Biol Chem 2013, 288(April (15)):10692-10702.
83. Demangel C., Bertolino P., Britton W.J. Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production. Eur J Immunol 2002, 32(April (4)):994-1002.
84. Redford P.S., Murray P.J., O'Garra A. The role of IL-10 in immune regulation during M. tuberculosis infection. Mucosal Immunol 2011, 4(May (3)):261-270.
85. Du P.N., Loebenberg L., Kriel M., von Groote-Bidlingmaier F., Ribechini E., Loxton A.G., et al. Increased frequency of myeloid-derived suppressor cells during active tuberculosis and after recent Mycobacterium tuberculosis infection suppresses T-cell function. Am J Respir Crit Care Med 2013, 188(September (6)):724-732.
86. Tsiganov E.N., Verbina E.M., Radaeva T.V., Sosunov V.V., Kosmiadi G.A., Nikitina I.Y., et al. Gr-1dimCD11b+ immature myeloid-derived suppressor cells but not neutrophils are markers of lethal tuberculosis infection in mice. J Immunol 2014, 192(May (10)):4718-4727.
87. Obregon-Henao A., Henao-Tamayo M., Orme I.M., Ordway D.J. Gr1(int)CD11b+ myeloid-derived suppressor cells in Mycobacterium tuberculosis infection. PLOS ONE 2013, 8(11):e80669.
88. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9(March (3)):162-174.
89. Manca C., Tsenova L., Bergtold A., Freeman S., Tovey M., Musser J.M., et al. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha/beta. Proc Natl Acad Sci U S A 2001, 98(May (10)):5752-5757.
90. Stanley S.A., Johndrow J.E., Manzanillo P., Cox J.S. The Type I IFN response to infection with Mycobacterium tuberculosis requires ESX-1-mediated secretion and contributes to pathogenesis. J Immunol 2007, 178(March (5)):3143-3152.
91. Manzanillo P.S., Shiloh M.U., Portnoy D.A., Cox J.S. Mycobacterium tuberculosis activates the DNA-dependent cytosolic surveillance pathway within macrophages. Cell Host Microbe 2012, 11(May (5)):469-480.
92. Novikov A., Cardone M., Thompson R., Shenderov K., Kirschman K.D., Mayer-Barber K.D., et al. Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1beta production in human macrophages. J Immunol 2011, 187(September (5)):2540-2547.
93. Shah S., Bohsali A., Ahlbrand S.E., Srinivasan L., Rathinam V.A., Vogel S.N., et al. Cutting edge: Mycobacterium tuberculosis but not nonvirulent mycobacteria inhibits IFN-beta and AIM2 inflammasome-dependent IL-1beta production via its ESX-1 secretion system. J Immunol 2013, 191(October (7)):3514-3518.
94. Mayer-Barber K.D., Andrade B.B., Barber D.L., Hieny S., Feng C.G., Caspar P., et al. Innate and adaptive interferons suppress IL-1alpha and IL-1beta production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity 2011, 35(December (6)):1023-1034.
95. Shafiani S., Tucker-Heard G., Kariyone A., Takatsu K., Urdahl K.B. Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. J Exp Med 2010, 207(July (7)):1409-1420.
96. Shafiani S., Dinh C., Ertelt J.M., Moguche A.O., Siddiqui I., Smigiel K.S., et al. Pathogen-specific Treg cells expand early during Mycobacterium tuberculosis infection but are later eliminated in response to Interleukin-12. Immunity 2013, 38(June (6)):1261-1270.
97. Leepiyasakulchai C., Ignatowicz L., Pawlowski A., Kallenius G., Skold M. Failure to recruit anti-inflammatory CD103+ dendritic cells and a diminished CD4+ Foxp3+ regulatory T cell pool in mice that display excessive lung inflammation and increased susceptibility to Mycobacterium tuberculosis. Infect Immun 2012, 80(March (3)):1128-1139.
98. Almeida A.S., Lago P.M., Boechat N., Huard R.C., Lazzarini L.C., Santos A.R., et al. Tuberculosis is associated with a down-modulatory lung immune response that impairs Th1-type immunity. J Immunol 2009, 183(July (1)):718-731.
99. Bonecini-Almeida M.G., Ho J.L., Boechat N., Huard R.C., Chitale S., Doo H., et al. Down-modulation of lung immune responses by interleukin-10 and transforming growth factor beta (TGF-beta) and analysis of TGF-beta receptors I and II in active tuberculosis. Infect Immun 2004, 72(May (5)):2628-2634.
100. Barnes P.F., Lu S., Abrams J.S., Wang E., Yamamura M., Modlin R.L. Cytokine production at the site of disease in human tuberculosis. Infect Immun 1993, 61(August (8)):3482-3489.
101. Othieno C., Hirsch C.S., Hamilton B.D., Wilkinson K., Ellner J.J., Toossi Z. Interaction of Mycobacterium tuberculosis-induced transforming growth factor beta1 and interleukin-10. Infect Immun 1999, 67(November (11)):5730-5735.
102. Periasamy S., Dhiman R., Barnes P.F., Paidipally P., Tvinnereim A., Bandaru A., et al. Programmed death 1 and cytokine inducible SH2-containing protein dependent expansion of regulatory T cells upon stimulation with Mycobacterium tuberculosis. J Infect Dis 2011, 203(May (9)):1256-1263.
103. Garg A., Barnes P.F., Roy S., Quiroga M.F., Wu S., Garcia V.E., et al. Mannose-capped lipoarabinomannan- and prostaglandin E2-dependent expansion of regulatory T cells in human Mycobacterium tuberculosis infection. Eur J Immunol 2008, 38(February (2)):459-469.
104. Gerosa F., Nisii C., Righetti S., Micciolo R., Marchesini M., Cazzadori A., et al. CD4(+) T cell clones producing both interferon-gamma and interleukin-10 predominate in bronchoalveolar lavages of active pulmonary tuberculosis patients. Clin Immunol 1999, 92(September (3)):224-234.
105. Toossi Z., Gogate P., Shiratsuchi H., Young T., Ellner J.J. Enhanced production of TGF-beta by blood monocytes from patients with active tuberculosis and presence of TGF-beta in tuberculous granulomatous lung lesions. J Immunol 1995, 154(January (1)):465-473.
106. Dahl K.E., Shiratsuchi H., Hamilton B.D., Ellner J.J., Toossi Z. Selective induction of transforming growth factor beta in human monocytes by lipoarabinomannan of Mycobacterium tuberculosis. Infect Immun 1996, 64(February (2)):399-405.
107. Hirsch C.S., Yoneda T., Averill L., Ellner J.J., Toossi Z. Enhancement of intracellular growth of Mycobacterium tuberculosis in human monocytes by transforming growth factor-beta 1. J Infect Dis 1994, 170(November (5)):1229-1237.
108. Ding A., Nathan C.F., Graycar J., Derynck R., Stuehr D.J., Srimal S. Macrophage deactivating factor and transforming growth factors-beta 1 -beta 2 and -beta 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-gamma. J Immunol 1990, 145(August (3)):940-944.
109. Oren R., Farnham A.E., Saito K., Milofsky E., Karnovsky M.L. Metabolic patterns in three types of phagocytizing cells. J Cell Biol 1963, 17(June):487-501.
110. Wewers M.D., Rennard S.I., Hance A.J., Bitterman P.B., Crystal R.G. Normal human alveolar macrophages obtained by bronchoalveolar lavage have a limited capacity to release interleukin-1. J Clin Invest 1984, 74(December (6)):2208-2218.
111. Roth M.D., Golub S.H. Human pulmonary macrophages utilize prostaglandins and transforming growth factor beta 1 to suppress lymphocyte activation. J Leukoc Biol 1993, 53(April (4)):366-371.
112. Martinez F.O., Helming L., Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009, 27:451-483.
113. Nguyen B.Y., Peterson P.K., Verbrugh H.A., Quie P.G., Hoidal J.R. Differences in phagocytosis and killing by alveolar macrophages from humans, rabbits, rats, and hamsters. Infect Immun 1982, 36(May (2)):504-509.
114. Lyons C.R., Ball E.J., Toews G.B., Weissler J.C., Stastny P., Lipscomb M.F. Inability of human alveolar macrophages to stimulate resting T cells correlates with decreased antigen-specific T cell-macrophage binding. J Immunol 1986, 137(August (4)):1173-1180.
115. Holt P.G. Alveolar macrophages. III. Studies on the mechanisms of inhibition of T-cell proliferation. Immunology 1979, 37(June (2)):437-445.
116. Leemans J.C., Juffermans N.P., Florquin S., van R.N., Vervoordeldonk M.J., Verbon A., et al. Depletion of alveolar macrophages exerts protective effects in pulmonary tuberculosis in mice. J Immunol 2001, 166(April (7)):4604-4611.
117. Tomlinson G.S., Bell L.C., Walker N.F., Tsang J., Brown J.S., Breen R., et al. HIV-1 infection of macrophages dysregulates innate immune responses to Mycobacterium tuberculosis by inhibition of interleukin-10. J Infect Dis 2014, 209(April (7)):1055-1065.
118. Sonnenberg P., Glynn J.R., Fielding K., Murray J., Godfrey-Faussett P., Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005, 191(January (2)):150-158.
119. Dorhoi A., Kaufmann S.H. Tumor necrosis factor alpha in mycobacterial infection. Semin Immunol 2014, 26(June (3)):203-209.
120. Moura-Alves P., Fae K., Houthuys E., Dorhoi A., Kreuchwig A., Furkert J., et al. AhR sensing of bacterial pigments regulates antibacterial defence. Nature 2014, 512(August):387-392.
121. Opitz C.A., Litzenburger U.M., Sahm F., Ott M., Tritschler I., Trump S., et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011, 478(October (7368)):197-203.
122. Clay H., Volkman H.E., Ramakrishnan L. Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity 2008, 29(August (2)):283-294.
123. Mootoo A., Stylianou E., Arias M.A., Reljic R. TNF-alpha in tuberculosis: a cytokine with a split personality. Inflamm Allergy Drug Targets 2009, 8(March (1)):53-62.
124. Roca F.J., Ramakrishnan L. TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species. Cell 2013, 153(April (3)):521-534.
125. Tobin D.M., Roca F.J., Oh S.F., McFarland R., Vickery T.W., Ray J.P., et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 2012, 148(February (3)):434-446.
126. Antonelli L.R., Gigliotti R.A., Goncalves R., Roffe E., Cheever A.W., Bafica A., et al. Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J Clin Invest 2010, 120(May (5)):1674-1682.
127. Desvignes L., Wolf A.J., Ernst J.D. Dynamic roles of type I and type II IFNs in early infection with Mycobacterium tuberculosis. J Immunol 2012, 188(June (12)):6205-6215.
128. Mayer-Barber K.D., Andrade B.B., Oland S.D., Amaral E.P., Barber D.L., Gonzales J., et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 2014, 511(July (7507)):99-103.
129. Coulombe F., Jaworska J., Verway M., Tzelepis F., Massoud A., Gillard J., et al. Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages. Immunity 2014, 40(April (4)):554-568.
130. Chen M., Divangahi M., Gan H., Shin D.S., Hong S., Lee D.M., et al. Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J Exp Med 2008, 205(November (12)):2791-2801.
131. Mishra B.B., Rathinam V.A., Martens G.W., Martinot A.J., Kornfeld H., Fitzgerald K.A., et al. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1beta. Nat Immunol 2013, 14(January (1)):52-60.
132. Nandi B., Behar S.M. Regulation of neutrophils by interferon-gamma limits lung inflammation during tuberculosis infection. J Exp Med 2011, 208(October (11)):2251-2262.
133. Heuts F., Gavier-Widen D., Carow B., Juarez J., Wigzell H., Rottenberg M.E. CD4+ cell-dependent granuloma formation in humanized mice infected with mycobacteria. Proc Natl Acad Sci U S A 2013, 110(April (16)):6482-6487.
134. Cooper A.M., Mayer-Barber K.D., Sher A. Role of innate cytokines in mycobacterial infection. Mucosal Immunol 2011, 4(May (3)):252-260.
135. Jayaraman P., Sada-Ovalle I., Nishimura T., Anderson A.C., Kuchroo V.K., Remold H.G., et al. IL-1beta promotes antimicrobial immunity in macrophages by regulating TNFR signaling and caspase-3 activation. J Immunol 2013, 190(April (8)):4196-4204.
136. Verway M., Bouttier M., Wang T.T., Carrier M., Calderon M., An B.S., et al. Vitamin D induces interleukin-1beta expression: paracrine macrophage epithelial signaling controls M. tuberculosis infection. PLoS Pathog 2013, 9(6):e1003407.
137. Torrado E., Cooper A.M. IL-17 and Th17 cells in tuberculosis. Cytokine Growth Factor Rev 2010, 21(December (6)):455-462.
138. Lockhart E., Green A.M., Flynn J.L. IL-17 production is dominated by gammadelta T cells rather than CD4T cells during Mycobacterium tuberculosis infection. J Immunol 2006, 177(October (7)):4662-4669.
139. Ramakrishnan L. Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol 2012, 12(May (5)):352-366.
140. Dannenberg A.M., Sugimoto M. Liquefaction of caseous foci in tuberculosis. Am Rev Respir Dis 1976, 113(March (3)):257-259.
141. Kaplan G., Post F.A., Moreira A.L., Wainwright H., Kreiswirth B.N., Tanverdi M., et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun 2003, 71(December (12)):7099-7108.
142. Rodrigo T., Cayla J.A., Garcia de O.P., Galdos-Tanguis H., Jansa J.M., Miranda P., et al. Characteristics of tuberculosis patients who generate secondary cases. Int J Tuberc Lung Dis 1997, 1(August (4)):352-357.
143. Seiler P., Aichele P., Bandermann S., Hauser A.E., Lu B., Gerard N.P., et al. Early granuloma formation after aerosol Mycobacterium tuberculosis infection is regulated by neutrophils via CXCR3-signaling chemokines. Eur J Immunol 2003, 33(October (10)):2676-2686.
144. Slight S.R., Khader S.A. Chemokines shape the immune responses to tuberculosis. Cytokine Growth Factor Rev 2013, 24(April (2)):105-113.
145. Kaneko H., Yamada H., Mizuno S., Udagawa T., Kazumi Y., Sekikawa K., et al. Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice. Lab Invest 1999, 79(April (4)):379-386.
146. Bean A.G., Roach D.R., Briscoe H., France M.P., Korner H., Sedgwick J.D., et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999, 162(March (6)):3504-3511.
147. Kindler V., Sappino A.P., Grau G.E., Piguet P.F., Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989, 56(March (5)):731-740.
148. Senaldi G., Yin S., Shaklee C.L., Piguet P.F., Mak T.W., Ulich T.R. Corynebacterium parvum- and Mycobacterium bovis bacillus Calmette-Guerin-induced granuloma formation is inhibited in TNF receptor I (TNF-RI) knockout mice and by treatment with soluble TNF-RI. J Immunol 1996, 157(December (11)):5022-5026.
149. Egen J.G., Rothfuchs A.G., Feng C.G., Winter N., Sher A., Germain R.N. Macrophage and T cell dynamics during the development and disintegration of mycobacterial granulomas. Immunity 2008, 28(February (2)):271-284.
150. Roach D.R., Bean A.G., Demangel C., France M.P., Briscoe H., Britton W.J. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002, 168(May (9)):4620-4627.
151. Wallis R.S. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008, 8(October (10)):601-611.
152. Kim M.J., Wainwright H.C., Locketz M., Bekker L.G., Walther G.B., Dittrich C., et al. Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol Med 2010, 2(July (7)):258-274.
153. Mehra S., Pahar B., Dutta N.K., Conerly C.N., Philippi-Falkenstein K., Alvarez X., et al. Transcriptional reprogramming in nonhuman primate (rhesus macaque) tuberculosis granulomas. PLoS ONE 2010, 5(8):e12266.
154. Subbian S., Tsenova L., O'Brien P., Yang G., Koo M.S., Peixoto B., et al. Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology. Am J Pathol 2011, 179(July (1)):289-301.
155. Ugarte-Gil C.A., Elkington P., Gilman R.H., Coronel J., Tezera L.B., Bernabe-Ortiz A., et al. Induced sputum MMP-1, -3 & -8 concentrations during treatment of tuberculosis. PLOS ONE 2013, 8(4):e61333.
156. Reece S.T., Loddenkemper C., Askew D.J., Zedler U., Schommer-Leitner S., Stein M., et al. Serine protease activity contributes to control of Mycobacterium tuberculosis in hypoxic lung granulomas in mice. J Clin Invest 2010, 120(September (9)):3365-3376.
157. Chamie G., Luetkemeyer A., Walusimbi-Nanteza M., Okwera A., Whalen C.C., Mugerwa R.D., et al. Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. Int J Tuberc Lung Dis 2010, 14(October (10)):1295-1302.
158. Li Y., Wang Y., Liu X. The role of airway epithelial cells in response to mycobacteria infection. Clin Dev Immunol 2012, 2012:791392.
159. Parker D., Prince A. Innate immunity in the respiratory epithelium. Am J Respir Cell Mol Biol 2011, 45(August (2)):189-201.
160. Sato K., Tomioka H., Shimizu T., Gonda T., Ota F., Sano C. Type II alveolar cells play roles in macrophage-mediated host innate resistance to pulmonary mycobacterial infections by producing proinflammatory cytokines. J Infect Dis 2002, 185(April (8)):1139-1147.
161. Bermudez L.E., Sangari F.J., Kolonoski P., Petrofsky M., Goodman J. The efficiency of the translocation of Mycobacterium tuberculosis across a bilayer of epithelial and endothelial cells as a model of the alveolar wall is a consequence of transport within mononuclear phagocytes and invasion of alveolar epithelial cells. Infect Immun 2002, 70(January (1)):140-146.
162. Hsu T., Hingley-Wilson S.M., Chen B., Chen M., Dai A.Z., Morin P.M., et al. The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue. Proc Natl Acad Sci U S A 2003, 100(October (21)):12420-12425.
163. Kinhikar A.G., Verma I., Chandra D., Singh K.K., Weldingh K., Andersen P., et al. Potential role for ESAT6 in dissemination of M. tuberculosis via human lung epithelial cells. Mol Microbiol 2010, 75(January (1)):92-106.
164. Castro-Garza J., King C.H., Swords W.E., Quinn F.D. Demonstration of spread by Mycobacterium tuberculosis bacilli in A549 epithelial cell monolayers. FEMS Microbiol Lett 2002, 212(July (2)):145-149.
165. Fine-Coulson K., Reaves B.J., Karls R.K., Quinn F.D. The role of lipid raft aggregation in the infection of type II pneumocytes by Mycobacterium tuberculosis. PLoS ONE 2012, 7(9):e45028.
166. Guo X.G., Ji T.X., Xia Y., Ma Y.Y. Autophagy protects type II alveolar epithelial cells from Mycobacterium tuberculosis infection. Biochem Biophys Res Commun 2013, 432(March (2)):308-313.
167. Bradfute S.B., Castillo E.F., Arko-Mensah J., Chauhan S., Jiang S., Mandell M., et al. Autophagy as an immune effector against tuberculosis. Curr Opin Microbiol 2013, 16(June (3)):355-365.
168. Watson R.O., Manzanillo P.S., Cox J.S. Extracellular M. tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathway. Cell 2012, 150(August (4)):803-815.
169. Castillo E.F., Dekonenko A., Arko-Mensah J., Mandell M.A., Dupont N., Jiang S., et al. Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation. Proc Natl Acad Sci U S A 2012, 109(November (46)):E3168-E3176.
170. Volkman H.E., Pozos T.C., Zheng J., Davis J.M., Rawls J.F., Ramakrishnan L. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 2010, 327(January (5964)):466-469.
171. Taylor J.L., Hattle J.M., Dreitz S.A., Troudt J.M., Izzo L.S., Basaraba R.J., et al. Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection. Infect Immun 2006, 74(November (11)):6135-6144.
172. Nouailles G., Dorhoi A., Koch M., Zerrahn J., Weiner J., Fae K.C., et al. CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis. J Clin Invest 2014, 124(March (3)):1268-1282.
173. Lin Y., Zhang M., Barnes P.F. Chemokine production by a human alveolar epithelial cell line in response to Mycobacterium tuberculosis. Infect Immun 1998, 66(March (3)):1121-1126.
174. Wickremasinghe M.I., Thomas L.H., Friedland J.S. Pulmonary epithelial cells are a source of IL-8 in the response to Mycobacterium tuberculosis: essential role of IL-1 from infected monocytes in a NF-kappa B-dependent network. J Immunol 1999, 163(October (7)):3936-3947.
175. Wickremasinghe M.I., Thomas L.H., O'Kane C.M., Uddin J., Friedland J.S. Transcriptional mechanisms regulating alveolar epithelial cell-specific CCL5 secretion in pulmonary tuberculosis. J Biol Chem 2004, 279(June (26)):27199-27210.
176. Sharma M., Sharma S., Roy S., Varma S., Bose M. Pulmonary epithelial cells are a source of interferon-gamma in response to Mycobacterium tuberculosis infection. Immunol Cell Biol 2007, 85(April (3)):229-237.
177. Roy S., Sharma S., Sharma M., Aggarwal R., Bose M. Induction of nitric oxide release from the human alveolar epithelial cell line A549: an in vitro correlate of innate immune response to Mycobacterium tuberculosis. Immunology 2004, 112(July (3)):471-480.
178. Feng C.G., Kaviratne M., Rothfuchs A.G., Cheever A., Hieny S., Young H.A., et al. NK cell-derived IFN-gamma differentially regulates innate resistance and neutrophil response in T cell-deficient hosts infected with Mycobacterium tuberculosis. J Immunol 2006, 177(November (10)):7086-7093.
179. Ulrichs T., Moody D.B., Grant E., Kaufmann S.H.E., Porcelli S.A. T-cell responses to CD1-presented lipid antigens in humans with Mycobacterium tuberculosis infection. Infect Immun 2003, 71(June (6)):3076-3087.
180. Lewinsohn D.A., Gold M.C., Lewinsohn D.M. Views of immunology: effector T cells. Immunol Rev 2011, 240(March (1)):25-39.
181. Flynn J.L., Goldstein M.M., Triebold K.J., Koller B., Bloom B.R. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A 1992, 89(December (24)):12013-12017.
182. Follows G.A., Munk M.E., Gatrill A.J., Conradt P., Kaufmann S.H. Gamma interferon and interleukin 2, but not interleukin 4, are detectable in gamma/delta T-cell cultures after activation with bacteria. Infect Immun 1992, 60(March (3)):1229-1231.
183. Barnes P.F., Grisso C.L., Abrams J.S., Band H., Rea T.H., Modlin R.L. Gamma delta T lymphocytes in human tuberculosis. J Infect Dis 1992, 165(March (3)):506-512.
184. Ladel C.H., Blum C., Dreher A., Reifenberg K., Kaufmann S.H. Protective role of gamma/delta T cells and alpha/beta T cells in tuberculosis. Eur J Immunol 1995, 25(October (10)):2877-2881.
185. Rivas-Santiago B., Contreras J.C., Sada E., Hernandez-Pando R. The potential role of lung epithelial cells and beta-defensins in experimental latent tuberculosis. Scand J Immunol 2008, 67(May (5)):448-452.
186. Rivas-Santiago B., Sada E., Tsutsumi V., Aguilar-Leon D., Contreras J.L., Hernandez-Pando R. beta-Defensin gene expression during the course of experimental tuberculosis infection. J Infect Dis 2006, 194(September (5)):697-701.
187. Rivas-Santiago B., Hernandez-Pando R., Carranza C., Juarez E., Contreras J.L., Aguilar-Leon D., et al. Expression of cathelicidin LL-37 during Mycobacterium tuberculosis infection in human alveolar macrophages, monocytes, neutrophils, and epithelial cells. Infect Immun 2008, 76(March (3)):935-941.
188. Castaneda-Delgado J., Hernandez-Pando R., Serrano C.J., Aguilar-Leon D., Leon-Contreras J., Rivas-Santiago C., et al. Kinetics and cellular sources of cathelicidin during the course of experimental latent tuberculous infection and progressive pulmonary tuberculosis. Clin Exp Immunol 2010, 161(September (3)):542-550.
189. Liu P.T., Stenger S., Tang D.H., Modlin R.L. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol 2007, 179(August (4)):2060-2063.
190. Apetoh L., Quintana F.J., Pot C., Joller N., Xiao S., Kumar D., et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol 2010, 11(September (9)):854-861.
191. Gandhi R., Kumar D., Burns E.J., Nadeau M., Dake B., Laroni A., et al. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol 2010, 11(September (9)):846-853.
192. Quintana F.J., Basso A.S., Iglesias A.H., Korn T., Farez M.F., Bettelli E., et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008, 453(May (7191)):65-71.
193. Veldhoen M., Hirota K., Westendorf A.M., Buer J., Dumoutier L., Renauld J.C., et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 2008, 453(May (7191)):106-109.
194. Khader S.A., Cooper A.M. IL-23 and IL-17 in tuberculosis. Cytokine 2008, 41(February (2)):79-83.
195. Pessanha A.P., Martins R.A., Mattos-Guaraldi A.L., Vianna A., Moreira L.O. Arginase-1 expression in granulomas of tuberculosis patients. FEMS Immunol Med Microbiol 2012, 66(November (2)):265-268.
196. El Kasmi K.C., Qualls J.E., Pesce J.T., Smith A.M., Thompson R.W., Henao-Tamayo M., et al. Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nat Immunol 2008, 9(December (12)):1399-1406.
197. Duque-Correa M.A., Kuhl A.A., Rodriguez P.C., Zedler U., Schommer-Leitner S., Rao M., et al. Macrophage arginase-1 controls bacterial growth and pathology in hypoxic tuberculosis granulomas. Proc Natl Acad Sci U S A 2014, 111(September (38)):E4024-E4032.
198. Rodriguez P.C., Quiceno D.G., Ochoa A.C. l-Arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007, 109(February (4)):1568-1573.
199. Munder M. Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol 2009, 158(October (3)):638-651.
200. Kaufmann S.H., Lange C., Rao M., Balaji K.N., Lotze M., Schito M., et al. Progress in tuberculosis vaccine development and host-directed therapies - a state of the art review. Lancet Respir Med 2014, 2(April (4)):301-320.
201. Berry M.P., Graham C.M., McNab F.W., Xu Z., Bloch S.A., Oni T., et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010, 466(August (7309)):973-977.
202. Maertzdorf J., Ota M., Repsilber D., Mollenkopf H.J., Weiner J., Hill P.C., et al. Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis. PLoS ONE 2011, 6(10):e26938.
203. Maertzdorf J., Repsilber D., Parida S.K., Stanley K., Roberts T., Black G., et al. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun 2011, 12(January (1)):15-22.
204. Ottenhoff T.H., Dass R.H., Yang N., Zhang M.M., Wong H.E., Sahiratmadja E., et al. Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PLoS ONE 2012, 7(9):e45839.
205. Bloom C.I., Graham C.M., Berry M.P., Rozakeas F., Redford P.S., Wang Y., et al. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLOS ONE 2013, 8(8):e70630.
206. Maertzdorf J., Weiner J., Mollenkopf H.J., Bauer T., Prasse A., Muller-Quernheim J., et al. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci U S A 2012, 109(May (20)):7853-7858.
207. Greenwood M. Professor Calmette's statistical study of B.C.G. vaccination. Br Med J 1928, 1(May (3514)):793-795.
208. Houk V.N., Baker J.H., Sorensen K., Kent D.C. The epidemiology of tuberculosis infection in a closed environment. Arch Environ Health 1968, 16(January (1)):26-35.
209. Israel H.L., Hetherington H.W., Ord J.G. A study of tuberculosis among students of nursing. J Am Med Assoc 1941, 117(839):844.
210. Mahan C.S., Zalwango S., Thiel B.A., Malone L.L., Chervenak K.A., Baseke J., et al. Innate and adaptive immune responses during acute M. tuberculosis infection in adult household contacts in Kampala, Uganda. Am J Trop Med Hyg 2012, 86(April (4)):690-697.
211. Morrison J., Pai M., Hopewell P.C. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis 2008, 8(June (6)):359-368.
212. Reiter H. Die Säuglingstuberkulose in Lübeck 1935, Julius Springer, Berlin.
213. Gold M.C., Cerri S., Smyk-Pearson S., Cansler M.E., Vogt T.M., Delepine J., et al. Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol 2010, 8(6):e1000407.
214. De Libero G., Singhal A., Lepore M., Mori L. Nonclassical T cells and their antigens in tuberculosis. Cold Spring Harb Perspect Med 2014, 4(June (9)). pii: a018473. 10.1101/cshperspect.a018473.
215. Russell D.G., Barry C.E., Flynn J.L. Tuberculosis: what we don't know can, and does, hurt us. Science 2010, 328(May (5980)):852-856.
216. Lin P.L., Ford C.B., Coleman M.T., Myers A.J., Gawande R., Ioerger T., et al. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med 2014, 20(January (1)):75-79.
217. Cilfone N.A., Perry C.R., Kirschner D.E., Linderman J.J. Multi-scale modeling predicts a balance of tumor necrosis factor-alpha and interleukin-10 controls the granuloma environment during Mycobacterium tuberculosis infection. PLOS ONE 2013, 8(7):e68680.